Rosuvastatin vs Atorvastatin: Which Statin Lowers LDL More?

LDL Cholesterol Reduction

Rosuvastatin consistently lowers LDL cholesterol more than atorvastatin at comparable doses. A 2025 meta-analysis of head-to-head trials found rosuvastatin reduced LDL by 55.66 mg/dL on average, compared to 51.49 mg/dL for atorvastatin. At the same 10 mg starting dose, rosuvastatin produced a 43% LDL reduction versus 35% for atorvastatin in a randomized trial of 516 patients. This difference matters most for patients who need aggressive LDL lowering but want to use the lowest effective dose.

Effects on Triglycerides and HDL

The differences extend beyond LDL. The same 2025 meta-analysis found rosuvastatin reduced triglycerides by 31.98 mg/dL versus 24.76 mg/dL for atorvastatin. Rosuvastatin also raised HDL cholesterol by 3.87 mg/dL compared to 1.85 mg/dL for atorvastatin. In the SATURN trial, after 104 weeks of maximum doses, rosuvastatin users had HDL levels of 50.4 mg/dL versus 48.6 mg/dL for atorvastatin (P=0.01). For patients with mixed dyslipidemia, these broader lipid improvements may tip the scale.

Cardiovascular Outcomes

Despite rosuvastatin’s stronger cholesterol reduction, head-to-head outcome data are surprisingly close. In the LODESTAR trial of 4,400 patients with coronary artery disease, the three-year composite of death, heart attack, stroke, or revascularization was nearly identical: 8.7% for rosuvastatin versus 8.2% for atorvastatin (HR 1.06, 95% CI 0.86 to 1.30). However, a large retrospective study of 136,680 patients found rosuvastatin associated with lower cardiovascular event risk (aRR 0.77, 95% CI 0.70 to 0.83) and lower stroke risk (aRR 0.76, 95% CI 0.62 to 0.94).

Coronary Plaque Regression

Both statins can reverse plaque buildup in coronary arteries. The SATURN trial used intravascular ultrasound to track plaque in 1,039 patients over 104 weeks. Both maximum-dose rosuvastatin (40 mg) and atorvastatin (80 mg) produced plaque regression, with 68.5% and 63.2% of patients showing improvement, respectively. Rosuvastatin achieved greater total atheroma volume reduction (6.39 mm³ versus 4.42 mm³, P=0.01) while percent atheroma volume changes were similar between groups.

Muscle-Related Side Effects

Muscle pain is the most common reason patients stop taking statins. A UK-based cohort study of 7,032 matched pairs found similar muscle event risk between rosuvastatin and atorvastatin (HR 1.17, 95% CI 0.88 to 1.56). A Veterans Affairs study comparing high-intensity doses told a different story: atorvastatin users had higher rates of muscle symptoms (1.14% versus 0.50%, OR 2.29, 95% CI 1.39 to 3.74) and stayed on therapy 2.5 times longer before developing problems with rosuvastatin.

Liver and Metabolic Differences

Each statin carries distinct secondary risks. In the LODESTAR trial, rosuvastatin users had higher rates of new-onset diabetes requiring medication (7.2% versus 5.3%, HR 1.39, 95% CI 1.03 to 1.87) and cataract surgery (2.5% versus 1.5%, HR 1.66, 95% CI 1.07 to 2.58). On the other hand, the VA study found atorvastatin caused more liver enzyme elevations (3.99% versus 1.39%, OR 2.95, 95% CI 2.21 to 3.94) and a higher overall adverse reaction rate (4.59% versus 2.91%).

Who Benefits From Each Statin

The choice often comes down to individual risk factors. Patients who need maximum LDL reduction at a lower dose, or who have existing liver concerns, may do better with rosuvastatin. Those with prediabetes or elevated diabetes risk might prefer atorvastatin. Pharmacogenomic research shows genetic variants in ABCG2 and SLCO1B1 genes can increase side effect risk differently for each drug, which may eventually guide more precise prescribing decisions.

Starting Statin Therapy

Both rosuvastatin and atorvastatin are effective, well-studied statins that reduce cardiovascular risk. The best statin is the one a patient will take consistently. Starting at a low dose and monitoring lipid response over 4 to 6 weeks allows physicians to adjust therapy based on individual results. Patients who have tried one statin and experienced side effects may tolerate the other well, since the two drugs have distinct metabolism pathways and different side effect profiles.